现代腋窝治疗后乳腺癌相关淋巴水肿发生率:我们的估计有多准确?
该研究于2020年7月至8月对全国外科医生和放射肿瘤科医生进行问卷调查,询问他们在不同腋窝干预后与患者讨论的乳腺癌相关淋巴水肿终生风险百分比。结果显示外科医生与放射肿瘤科医生对腋窝淋巴结清扫、前哨淋巴结活检联合区域淋巴结照射等术后淋巴水肿发生率的估计存在显著差异。结论指出提供者讨论的估计率存在变异性,需要医生教育以提供准确估计。
要点
- 外科医生对前哨淋巴结活检后淋巴水肿终生风险估计为5.7%,放射肿瘤科医生为5.0%(P = .03)。
- 外科医生对腋窝淋巴结清扫后淋巴水肿估计为21.8%,放射肿瘤科医生为17.5%(P < .001)。
- 外科医生对腋窝淋巴结清扫联合区域淋巴结照射后淋巴水肿估计为34.8%,放射肿瘤科医生为26.2%(P < .001)。
核心结论
- 提供者与患者讨论的乳腺癌相关淋巴水肿估计率存在变异性,需要医生教育以提供准确估计。
研究设计与样本
- 2020年7月至8月进行的全国性问卷调查,共680名外科医生和324名放射肿瘤科医生回复(回复率14%)。
主要发现
- 外科医生对前哨淋巴结活检后淋巴水肿终生风险估计为5.7%,放射肿瘤科医生为5.0%(P = .03)。
- 外科医生对腋窝淋巴结清扫后淋巴水肿估计为21.8%,放射肿瘤科医生为17.5%(P < .001)。
- 外科医生对前哨淋巴结活检联合区域淋巴结照射后淋巴水肿估计为14.1%,放射肿瘤科医生为11.2%(P < .001)。
- 外科医生对腋窝淋巴结清扫联合区域淋巴结照射后淋巴水肿估计为34.8%,放射肿瘤科医生为26.2%(P < .001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Clinical trials have demonstrated methods to minimize the risk of breast cancer-related lymphedema while preserving regional control. We sought to determine the percent lifetime-risk of breast cancer-related lymphedema that surgeons and radiation oncologists discuss with patients before axillary interventions. METHODS: A nationwide survey of surgeons and radiation oncologists was performed from July to August 2020. Participants were asked to identify what number they discuss with patients when estimating the percent lifetime-risk of breast cancer-related lymphedema after different axillary interventions. RESULTS: Six hundred and eighty surgeons and 324 radiation oncologists responded (14% response rate). While the estimated rate after sentinel lymph node biopsy was clinically similar between surgeons and radiation oncologists, statistically surgeons quoted a higher percent lifetime-risk (5.7% vs 5.0%, P = .03). Surgeons estimated significantly higher rates of breast cancer-related lymphedema compared with radiation oncologists (P < .001) for axillary lymph node dissection (21.8% vs 17.5%), sentinel lymph node biopsy with regional nodal irradiation (14.1% vs 11.2%), and axillary lymph node dissection with regional nodal irradiation (34.8% vs 26.2%). CONCLUSION: There is variability in the estimated rates of breast cancer-related lymphedema providers discuss with patients. These findings highlight the need for physician education on the current evidence of percent lifetime-risk of breast cancer-related lymphedema to provide patients with accurate estimates before axillary interventions.
引用
- Cortina CS, Yen TWF, Bergom C, et al. Breast cancer-related lymphedema rates after modern axillary treatments: How accurate are our estimates? Surgery. 2021. PMID: 34736790. doi:10.1016/j.surg.2021.08.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。